The Dedicated Product NorLevo is Now Available Over the Counter in France
On June 1st, 1999, HRA Pharma's NorLevo was granted over the counter status in France. This is the first dedicated emergency contraceptive product to receive such status in a major market. NorLevo was approved last November, but was not launched until May 30th of this year because the company was awaiting a decision on its legal status.
NorLevo is a progestin-only emergency contraceptive and contains no estrogen. Progestin-only ECPs are more effective than combined ECPs (containing both estrogen and progestin) and cause fewer side effects. Therapy is more effective the earlier it is initiated within the 72 hour window.
NorLevo will compete with Tetragynon, (known in other countries as PC4), the Schering AG emergency contraceptive product that was introduced in France this past January. NorLevo will be marketed by Laboratories Besins-Iscovesco, and will cost approximately $8.70. France's social security program will not refund any of this cost.